



1 September 2022

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000

technegas  
ultralute

Cyclopharm Ltd  
ABN 74 116 931 250  
Unit 4, 1 The Crescent  
Kingsgrove NSW 2208 Australia  
T 61 2 9541 0411  
F 61 2 9543 0960  
www.cyclopharm.com.au

### **Cyclopharm appoints Kevin Barrow as a non-executive director**

The board of Cyclopharm Limited, (ASX:CYC), is pleased to announce the appointment of Mr Kevin Barrow as a Non-Executive director, with the appointment effective today. Mr Barrow brings to the Cyclopharm board more than 20 years of experience in the healthcare industry, which includes numerous governance and senior executive roles.

Mr Barrow is currently Chief Executive Officer of the Butterfly Foundation, Australia's national charity providing clinical services and support to address eating disorders and body image issues. Prior to this role, Mr Barrow was the Managing Director at Philips Australia and New Zealand overseeing all Philips' operations in the region, while also direct General Manager for the Healthcare division, a leader in cardiac care, acute care and home healthcare.

Mr Barrow joined Philips from BD, (Becton, Dickinson and Company), a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. Mr Barrow was the Managing Director for BD Australia and New Zealand a market leader in the Medical, Diagnostic and Lifescience sector. Prior to this, Mr Barrow held several senior sales and marketing management roles at pharmaceutical company Eli Lilly.

Mr Barrow is a non-executive director of Wandi Nerida, Australia's first residential recovery centre for people affected by an eating disorder and was previously Chair of the Medical Technology Association of Australia (MTAA), where he was a director between 2009 and 2014.

Mr Barrow was born in New Zealand and holds a Master of Science (with 1st Class Honours) from the Waikato University, New Zealand. He obtained an MBA from the Macquarie Graduate School of Management, Sydney, Australia and is a graduate of the Australian Institute of Company Directors.

**David Heaney**, Cyclopharm Chair said, *"I am pleased the Board has appointed Kevin as a Non-Executive director. His extensive pharma, medical device and diagnostic imaging background will add significant value to the Cyclopharm Board."*

**Kevin Barrow** said, *"I am delighted to join the Board of Cyclopharm at such an exciting time for the business. Cyclopharm is a clear leader in diagnostic lung imaging with its Technegas® technology already used to manage Pulmonary Embolism in over 60 countries. I'm particularly excited by the imminent roll out of Technegas® in the US and the opportunity to broaden Technegas® into exponentially larger markets globally, such as COPD and Asthma."*

**James McBrayer**, Cyclopharm Managing Director, said, *"I look forward to working with Kevin to guide the business through its next growth phase. His extensive experience and insights into the medical devices and diagnostic imaging industry in particular will be invaluable as we deliver Cyclopharm's strategic goals."*

[ENDS]

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

**For more information, please refer to our website at [www.cyclopharm.com](http://www.cyclopharm.com) or contact:**

Mr James McBrayer  
Managing Director, CEO and Company Secretary  
Cyclopharm Limited  
T: +61 (02) 9541 0411

**Cyclopharm Limited**

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas™ used in functional lung ventilation imaging.

**Technegas™**

The Technegas™ technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas™, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.